Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Cromoglicate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Respivant Sciences Supports International Rare Disease Day Through Awareness Activities
Details : Respivant also announces 50% enrollment milestone achieved in SCENIC, a Phase 2b Trial of RVT-1601 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2020
Lead Product(s) : Sodium Cromoglicate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable